tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NGNE Stock Latest News

Neurogene Inc. Reports Q3 2025 Financial Results
Company AnnouncementsNeurogene Inc. Reports Q3 2025 Financial Results
3d ago
NGNE
Neurogene’s NGN-401: Strong Clinical Results and Market Misalignment Justify Buy Rating
PremiumRatings
Neurogene’s NGN-401: Strong Clinical Results and Market Misalignment Justify Buy Rating
4d ago
NGNE
Promising Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment: Analyst Recommends ‘Buy’
PremiumRatings
Promising Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment: Analyst Recommends ‘Buy’
4d ago
NGNE
Positive Developments and Financial Stability Underpin Buy Rating for Neurogene’s ‘401 Program
PremiumRatings
Positive Developments and Financial Stability Underpin Buy Rating for Neurogene’s ‘401 Program
4d ago
NGNE
Neurogene Reports Positive Interim Results for Rett Syndrome Gene Therapy
PremiumCompany Announcements
Neurogene Reports Positive Interim Results for Rett Syndrome Gene Therapy
7d ago
NGNE
Neurogene reports Q3 EPS (99c) vs. ($1.19) last year
PremiumThe FlyNeurogene reports Q3 EPS (99c) vs. ($1.19) last year
7d ago
NGNE
Neurogene’s NGN-401: Advancements and Growth Potential Drive Buy Rating and Raised Price Target
Premium
Ratings
Neurogene’s NGN-401: Advancements and Growth Potential Drive Buy Rating and Raised Price Target
8d ago
NGNE
Neurogene price target raised to $70 from $65 at H.C. Wainwright
Premium
The Fly
Neurogene price target raised to $70 from $65 at H.C. Wainwright
8d ago
NGNE
Neurogene’s NGN-401: Promising Phase I/II Results and Strategic Advancements Justify Buy Rating
PremiumRatings
Neurogene’s NGN-401: Promising Phase I/II Results and Strategic Advancements Justify Buy Rating
8d ago
NGNE
Neurogene Announces Positive Interim Data for NGN-401
PremiumCompany Announcements
Neurogene Announces Positive Interim Data for NGN-401
8d ago
8K
NGNE
Neurogene reports interim data in Pediatric Cohort from NGN-401 trial
PremiumThe Fly
Neurogene reports interim data in Pediatric Cohort from NGN-401 trial
9d ago
NGNE
Optimistic Buy Rating for Neurogene: Advancements in NGN-401 Therapy and Strategic Developments
PremiumRatings
Optimistic Buy Rating for Neurogene: Advancements in NGN-401 Therapy and Strategic Developments
14d ago
NGNE
Neurogene Positioned for Market Leadership with Advancements in Rett Syndrome Gene Therapy
PremiumRatingsNeurogene Positioned for Market Leadership with Advancements in Rett Syndrome Gene Therapy
15d ago
NGNE
Neurogene doses first patient in NGN-401 clinical trial
Premium
The Fly
Neurogene doses first patient in NGN-401 clinical trial
15d ago
NGNE
Neurogene Begins Dosing in Rett Syndrome Trial
Premium
Company Announcements
Neurogene Begins Dosing in Rett Syndrome Trial
15d ago
8K
NGNE
Neurogene price target raised to $65 from $45 at H.C. Wainwright
PremiumThe Fly
Neurogene price target raised to $65 from $45 at H.C. Wainwright
21d ago
NGNE
Neurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome
PremiumCompany Announcements
Neurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome
25d ago
NGNE
Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating
PremiumRatings
Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating
1M ago
NGNE
Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation
PremiumRatings
Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation
1M ago
NGNE
Neurogene Completes FDA Talks for Rett Syndrome Trial
PremiumCompany AnnouncementsNeurogene Completes FDA Talks for Rett Syndrome Trial
1M ago
8K
NGNE
Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data
Premium
The Fly
Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data
1M ago
NGNE
Neurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target
Premium
Ratings
Neurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target
2M ago
NGNE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >